Education
About Us
Working with TipRanks
Follow Us
Veracyte Inc (VCYT)
NASDAQ:VCYT
VCYT Stock Chart & Stats
$33.85
$0.68(1.60%)
At close: 4:00 PM EST
$33.85
$0.68(1.60%)
Day’s Range― - ―
52-Week Range$22.61 - $50.71
Previous CloseN/A
Volume253.49K
Average Volume (3M)883.38K
Market Cap
$2.69B
Enterprise Value$2.37B
Total Cash (Recent Filing)$412.89M
Total Debt (Recent Filing)$39.65M
Price to Earnings (P/E)49.9
Beta1.22
Next Earnings
May 12, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.53
Shares Outstanding79,458,430
10 Day Avg. Volume1,019,199
30 Day Avg. Volume883,382
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.53
Price to Sales (P/S)6.40
P/FCF Ratio26.13
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue4.58
Enterprise Value/Gross Profit6.48
Enterprise Value/Ebitda28.39
Forecast
1Y Price Target
$44.50Price Target Upside31.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)1.66
Revenue Forecast (FY)$575.76M
Bulls Say, Bears Say
Bulls Say
Pipeline CommercializationUpcoming launches of TrueMRD, a Prosigna laboratory-developed test and the Percepta nasal swab could expand addressable markets and materially increase revenue if reimbursement and clinician uptake progress.
Profitability And Cash PositionRising gross margin and adjusted EBITDA, combined with a debt-free balance sheet and positive cash flow, provide capital to reinvest in growth while preserving attractive profitability.
Test Volume GrowthSustained expansion in Decipher and Afirma test volumes indicates increasing physician adoption and drives revenue momentum, supporting upside to forecasts.
Bears Say
Commercial Adoption And Market ShareUncertainty around winning share from entrenched competitors and deepening Afirma penetration means commercial adoption may fall short of optimistic projections.
Execution Risk And Product TransitionsOngoing product transitions and multiple pipeline launches increase execution risk, creating the potential for delays or setbacks that could temper revenue expectations.
Valuation And Analyst SentimentCurrent valuation already incorporates much of the anticipated growth, and a Hold analyst view signals limited near-term share appreciation without stronger evidence of sustained outperformance.
Veracyte News
VCYT FAQ
What was Veracyte Inc’s price range in the past 12 months?
Veracyte Inc lowest stock price was $22.61 and its highest was $50.71 in the past 12 months.
What is Veracyte Inc’s market cap?
Veracyte Inc’s market cap is $2.69B.
When is Veracyte Inc’s upcoming earnings report date?
Veracyte Inc’s upcoming earnings report date is May 12, 2026 which is in 64 days.
How were Veracyte Inc’s earnings last quarter?
Veracyte Inc released its earnings results on Feb 25, 2026. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.409 by $0.121.
Is Veracyte Inc overvalued?
According to Wall Street analysts Veracyte Inc’s price is currently Undervalued.
Does Veracyte Inc pay dividends?
Veracyte Inc does not currently pay dividends.
What is Veracyte Inc’s EPS estimate?
Veracyte Inc’s EPS estimate is 0.34.
How many shares outstanding does Veracyte Inc have?
Veracyte Inc has 79,458,430 shares outstanding.
What happened to Veracyte Inc’s price movement after its last earnings report?
Veracyte Inc reported an EPS of $0.53 in its last earnings report, beating expectations of $0.409. Following the earnings report the stock price went up 8.483%.
Which hedge fund is a major shareholder of Veracyte Inc?
Currently, no hedge funds are holding shares in VCYT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veracyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$44.50 (31.46% Upside)
$44.50 (31.46% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 821.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.12%
12-Months-Change
Fundamentals
Return on Equity
5.34%
Trailing 12-Months
Asset Growth
7.74%
Trailing 12-Months
Company Description
Veracyte Inc
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT Company Deck
VCYT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a largely positive operational and financial story: robust revenue and volume growth, strong margins and cash generation, successful transition to a lower-cost transcriptome platform, substantial clinical evidence and data assets, and a clear product launch roadmap (TrueMRD and Prosigna) that sets up multi-year growth. Headwinds and risks were acknowledged—one-time prior-period collections (PPCs) amplified 2025 results and complicate comparability; planned investments and launch-related spending will temper margins in 2026; reimbursement timelines and near-term revenue contribution for new products (MRD, Prosigna, Percepta/NIGHTINGALE) remain uncertain. On balance, the highlights (top-line momentum, margins, cash, platform readiness, evidence generation, and pipeline) significantly outweigh the lowlights, which are mostly timing, one-time, or investment-related risks.View all VCYT earnings summariesVCYT Stock 12 Month Forecast
Average Price Target
$44.50
▲(31.46% Upside)
Technical Analysis
Travere Therapeutics
―
Celcuity
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
Currently, No data available
---